[Clinical and experimental studies with the antihistaminic Tavegyl in dermatologic patients].
D002986:Clinical Trials as Topic; D003877:Dermatitis, Contact / Q000188:drug therapy; D003875:Drug Eruptions / Q000188:drug therapy; D005076:Exanthema / Q000188:drug therapy; D005260:Female; D005650:Fumarates / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000188:drug therapy; D009450:Neurodermatitis / Q000188:drug therapy; D011537:Pruritus; D011759:Pyrrolidines / Q000627:therapeutic use; D012532:Scabies / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D014581:Urticaria / Q000188:drug therapy
D005650:Fumarates; D006634:Histamine H1 Antagonists; D011759:Pyrrolidines
Klinische und experimentelle Studien mit dem Antihistaminikum Tavegyl an dermatologischem Krankengut.